DE69839640D1 - Kombinationszusammensetzungen für die lyme-erkrankung und anwendungen - Google Patents

Kombinationszusammensetzungen für die lyme-erkrankung und anwendungen

Info

Publication number
DE69839640D1
DE69839640D1 DE69839640T DE69839640T DE69839640D1 DE 69839640 D1 DE69839640 D1 DE 69839640D1 DE 69839640 T DE69839640 T DE 69839640T DE 69839640 T DE69839640 T DE 69839640T DE 69839640 D1 DE69839640 D1 DE 69839640D1
Authority
DE
Germany
Prior art keywords
antigen
compositions
pathogen
lyme disease
borrelia burgdorferi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839640T
Other languages
English (en)
Inventor
Judy Jarecki-Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merial Ltd
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Application granted granted Critical
Publication of DE69839640D1 publication Critical patent/DE69839640D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0225Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/828Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/829Bacterial vaccine for equine species, e.g. horses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • Y10S977/802Virus-based particle
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
DE69839640T 1997-03-05 1998-03-04 Kombinationszusammensetzungen für die lyme-erkrankung und anwendungen Expired - Lifetime DE69839640D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/812,348 US6368603B1 (en) 1997-03-05 1997-03-05 Lyme combination compositions and uses
PCT/US1998/004135 WO1998039028A1 (en) 1997-03-05 1998-03-04 Lyme combination compositions and uses

Publications (1)

Publication Number Publication Date
DE69839640D1 true DE69839640D1 (de) 2008-08-07

Family

ID=25209312

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839640T Expired - Lifetime DE69839640D1 (de) 1997-03-05 1998-03-04 Kombinationszusammensetzungen für die lyme-erkrankung und anwendungen

Country Status (16)

Country Link
US (1) US6368603B1 (de)
EP (1) EP0988051B1 (de)
JP (1) JP4301415B2 (de)
CN (1) CN1252730A (de)
AT (1) ATE399021T1 (de)
AU (1) AU746185B2 (de)
BR (1) BR9808821A (de)
CA (1) CA2283420C (de)
DE (1) DE69839640D1 (de)
DK (1) DK0988051T3 (de)
ES (1) ES2310004T3 (de)
HU (1) HU228709B1 (de)
IL (2) IL131678A0 (de)
PL (1) PL190989B1 (de)
PT (1) PT988051E (de)
WO (1) WO1998039028A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU758764B2 (en) * 1998-03-02 2003-03-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Epitope peptides immunogenic against (streptococcus pneumoniae)
AU5622800A (en) * 1999-06-18 2001-01-09 Med Immune, Inc. Combined decorin binding protein and outer surface protein compositions and methods of use
DE10162434A1 (de) * 2001-12-18 2003-09-25 November Ag Molekulare Medizin Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US20040197339A1 (en) * 2003-01-29 2004-10-07 Brown Paul R. Vaccine for Lyme disease
EP2390352A1 (de) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systeme und Methoden zur Erhöhung der Milchproduktion bei Tieren
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
EP1718770B1 (de) 2004-02-19 2011-05-25 The Governors of the University of Alberta Leptinpromotor-polymorphismen und verwendungen davon
ES2343270T3 (es) 2005-04-25 2010-07-27 Merial Ltd. Vacunas contra el virus nipah.
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP3536704B1 (de) 2005-11-14 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Gentherapie für nierenversagen
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
JP5177824B2 (ja) 2006-11-03 2013-04-10 シェーリング−プラウ・リミテッド イヌのライム病のワクチン
KR101445903B1 (ko) 2007-05-02 2014-09-29 메리얼 리미티드 향상된 발현 및 안정성을 갖는 dna 플라스미드
US8871220B2 (en) 2009-04-03 2014-10-28 Merial Limited Newcastle disease virus vectored avian vaccines
US8623375B2 (en) * 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
CN103269714B (zh) 2010-08-31 2016-06-29 梅里亚有限公司 以新城疫病毒为载体的疱疹病毒疫苗
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
AU2012240246A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
EP2694677A2 (de) 2011-04-04 2014-02-12 Netherland Cancer Institute Verfahren und zusammensetzungen zur vorhersage der resistenz gegenüber einer antikrebsbehandlung mit proteinkinasehemmern
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CN103945864A (zh) 2011-04-25 2014-07-23 先进生物学实验室股份有限公司 截短的hiv包膜蛋白(env)、其相关方法和组合物
US9669085B2 (en) 2011-06-01 2017-06-06 Merial Inc. Needle-free administration of PRRSV vaccines
WO2013025274A1 (en) 2011-08-12 2013-02-21 Merial Limited Vacuum -assisted preservation of biological products, in particular of vaccines
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
NZ731659A (en) 2014-11-03 2018-10-26 Merial Inc Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CN107922462B (zh) 2015-06-23 2022-03-18 勃林格殷格翰动物保健美国公司 含prrsv次要蛋白的重组病毒载体及其制造方法与用途
KR20180129949A (ko) 2016-04-14 2018-12-05 메리얼 인코포레이티드 항균성 폴리아미드 또는 옥테니딘 보존제를 함유하는 다중-투약량 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5266313A (en) 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
EP1016416A3 (de) * 1990-07-06 2002-10-23 Wyeth Impfstoff gegen die Lyme-Krankheit und Modell zur Überwachung der Impfstoffwirksamkeit
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
AU2917892A (en) 1991-11-12 1993-06-15 Regents Of The University Of Minnesota Recombinant vaccine against lyme disease
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US5728385A (en) * 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives

Also Published As

Publication number Publication date
ATE399021T1 (de) 2008-07-15
US6368603B1 (en) 2002-04-09
JP2001513112A (ja) 2001-08-28
EP0988051B1 (de) 2008-06-25
AU746185B2 (en) 2002-04-18
CA2283420C (en) 2008-07-22
HUP0001401A3 (en) 2005-10-28
HUP0001401A2 (en) 2000-07-28
PL190989B1 (pl) 2006-02-28
CN1252730A (zh) 2000-05-10
DK0988051T3 (da) 2008-10-13
JP4301415B2 (ja) 2009-07-22
BR9808821A (pt) 2000-10-24
PL335731A1 (en) 2000-05-08
CA2283420A1 (en) 1998-09-11
EP0988051A4 (de) 2004-11-17
IL131678A0 (en) 2001-03-19
HU228709B1 (en) 2013-05-28
IL131678A (en) 2006-12-31
EP0988051A1 (de) 2000-03-29
WO1998039028A1 (en) 1998-09-11
PT988051E (pt) 2008-08-13
AU6680798A (en) 1998-09-22
ES2310004T3 (es) 2008-12-16

Similar Documents

Publication Publication Date Title
DE69839640D1 (de) Kombinationszusammensetzungen für die lyme-erkrankung und anwendungen
ATE398676T2 (de) Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
EA200300137A1 (ru) Анти-il-12-антитела, композиции, способы и применения
ATE438638T1 (de) Sulfoniumsalze als photoinitiatoren für strahlungshärtbare systeme
BR0314095A (pt) Catalisador para a produção de olefinas leves
WO2005035441A3 (en) Subtituted fullerene compositions and their use as antioxydants
DE60115717D1 (de) Antriebstrang für Fahrzeug
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
ATE208611T1 (de) Flubendazole-kautabletten für haustiere
DE69729190D1 (de) Datenstruktur zur unterstützung von mehreren datenübertragungspaketen für hohe leistung
ATE210078T1 (de) Hybride kieselsäure-zeolith zusammensetzung
BRPI0417167A (pt) composições para animais de estimação compreendendo oligofrutose de cadeia curta
ATE236153T1 (de) 4-trifluormethyl-3-oxazolylpyridine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schädlingsbekämpfungsmittel
ID24903A (id) Komposisi-komposisi, kit, dan metode untuk menghambat gangguan neurovaskular serebral dan sakit kepala muskular
ITMI20022712A1 (it) Composizione catalitica e processo per la transalchilazione di idrocarburi.
DE602004012111D1 (de) Ein phosphatbindemittel enthaltende zusammensetzung und deren herstellung
RU2009120894A (ru) Вакцина против лаймской болезни собак
BR0210493A (pt) Composição, e, método para remover cerume humano
BR0211643A (pt) Melhoras em ou relativas à composições de goma de mastigação
BR0011339A (pt) Composto, uso, e processo para preparar o mesmo, composição farmacêutica, e, método para tratar uma condição de doença mediada por metaloproteinase
ATE437780T1 (de) Verlustleistungsmanagementsystem
BR0115049A (pt) Processo para a interligação de diferentes grupos em foco assim como um sistema adequado para tal
DE602004023311D1 (de) Antigen-zufuhrsystem
BR0112185A (pt) Método para preparar pantotenato de cálcio
BR0309008A (pt) polipeptìdeos de micoplasma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition